Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.52 |
| ▸ | CNR2 | P34972 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4331291 | 0.93 | CNR1 (0.61) | CNR1CNR2MAPTKDM4EPOLB | |
| SCHEMBL4334559 | 0.87 | CNR2 (0.62) | CNR1CNR2MAPTKDM4EPOLB | |
| SCHEMBL4326279 | 0.87 | CNR1 (0.50) | CNR1CNR2 | |
| SCHEMBL4334584 | 0.87 | CNR2 (0.57) | CNR1CNR2KDM4EKMT2ANPC1 | |
| SCHEMBL4333482 | 0.85 | CNR2 (0.52) | CNR1CNR2 | |
| SCHEMBL4327706 | 0.85 | CNR1 (0.62) | CNR1CNR2KMT2ANPC1RAB9A | |
| SCHEMBL4325964 | 0.84 | CNR2 (0.52) | CNR1CNR2KDM4EPOLBKMT2A | |
| SCHEMBL4333588 | 0.83 | CNR1 (0.52) | CNR1CNR2L3MBTL1 | |
| SCHEMBL4331211 | 0.83 | CNR1 (0.56) | CNR1CNR2MAPTPOLBKMT2A | |
| SCHEMBL4324697 | 0.82 | CNR2 (0.54) | CNR1CNR2KDM4EKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | CNR1 2/4885CNR2 1/4885MAPT 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.